Alkermes shares are trading higher in a sympathy move tied to renewed investor focus on orexin biology in narcolepsy and adjacent sleep-wake disorders. The catalyst is Eli Lilly’s agreement to acquire Centessa, a deal widely viewed as a major endorsement of the orexin category and a potential reset point for how investors value late-stage sleep assets. That sentiment has flowed into publicly traded peers with orexin programs and narcolepsy exposure, including Alkermes, which is advancing alixorexton and ALKS 2680 and has recently broadened its commercial footprint in sleep medicine via the Avadel acquisition.

Alkermes’ near-term equity sensitivity is increasingly tied to the orexin franchise, where investors are watching for Phase 3 execution and data timing in narcolepsy, plus follow-on readouts that can clarify differentiation versus other orexin programs. Separately, the company’s Q1 2026 completion of the Avadel transaction positioned Alkermes with a marketed sleep product and a clearer platform narrative: a commercial sleep base plus a pipeline of next-generation orexin agonists. In an M&A tape that is rewarding assets with strong category momentum, that combination can tighten perceived strategic optionality and improve sentiment even without a same-day company-specific headline.

Key watch items for ALKS include any updates on Phase 3 progress for alixorexton in narcolepsy (trial start, enrollment pace, and topline timing), incremental clinical updates across the orexin portfolio, and post-acquisition execution signals from the combined Alkermes-Avadel sleep business (launch dynamics, payer traction, and 2026 revenue cadence). Investors will also monitor whether additional strategic deals emerge in sleep medicine following Lilly’s Centessa move, which could keep momentum elevated for the whole orexin cohort.